Wanhuida Intellectual Property

Wu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations involving active ingredients that are chemically reactive

Honghui Hu of Wanhuida Intellectual Property examines how the Supreme People’s Court has clarified the patent scope of drug combination inventions in a patent linkage dispute, offering rare guidance on claim interpretation of pharmaceutical combinations

Zhigang Zhu, Xiaoyang Yang, and Feng Zheng of Wanhuida Intellectual Property outline the intellectual property-related challenges Chinese enterprises face in pursuing growth through overseas expansion, and explain the steps that can help navigate the complexities

Yue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for the crystalline form of lemborexant and explains the implications for pharmaceutical patent strategies in China

Jicheng Yang and Jianhui Li of Wanhuida Intellectual Property draw on insights from CNIPA practice in discussing how different drafting approaches to crystal form patent claims impact protection scope and patent validity

Wu Xiaoping of Wanhuida Intellectual Property says the methodology often applied in assessing inventiveness in pharmaceutical patent litigation cases is set to be used in re-examination and invalidation proceedings after the CNIPA makes an invalidation decision a quasi-precedent